Stocktoria
Cresco Labs Inc. CRLBF
OTC · OOTC · stock · Medicinal Chemicals & Botanical Products · website · IPO 2018-12-03
Cresco Labs Inc. financials (annual, from 10-K)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $655.8M | $724.3M | $770.9M |
| Gross profit | $324.6M | $364.5M | $362.4M |
| SG&A expense | $247.5M | $254.8M | $299.2M |
| Operating income | -$28.0M | $107.3M | -$87.8M |
| Income tax | $44.6M | $49.9M | $33.0M |
| Net income | -$135.4M | -$74.4M | -$175.5M |
| EPS (diluted) | $-0.38 | $-0.22 | $-0.54 |
| Operating cash flow | $72.9M | $132.5M | $58.6M |
| Free cash flow | $37.8M | $113.0M | $3.2M |
| Cash & equivalents | $57.9M | $137.6M | $103.4M |
| Inventory | $98.7M | $83.3M | $107.8M |
| Total assets | $1.2B | $1.4B | $1.4B |
| Total liabilities | $944.8M | $967.2M | $930.4M |
| Shareholders' equity | $340.4M | $474.9M | $505.7M |
Growth · year-over-year · Revenue CAGR -7.8%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | -9.5% | -6.0% | — |
| Free cash flow growth | -66.6% | +3454.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001832928 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.